Skip to main content

Envisioning is an emerging technology research institute and advisory.

LinkedInInstagramGitHub

2011 — 2026

research
  • Reports
  • Newsletter
  • Methodology
  • Origins
  • Vocab
services
  • Research Sessions
  • Signals Workspace
  • Bespoke Projects
  • Use Cases
  • Signal Scanfree
  • Readinessfree
impact
  • ANBIMAFuture of Brazilian Capital Markets
  • IEEECharting the Energy Transition
  • Horizon 2045Future of Human and Planetary Security
  • WKOTechnology Scanning for Austria
audiences
  • Innovation
  • Strategy
  • Consultants
  • Foresight
  • Associations
  • Governments
resources
  • Pricing
  • Partners
  • How We Work
  • Data Visualization
  • Multi-Model Method
  • FAQ
  • Security & Privacy
about
  • Manifesto
  • Community
  • Events
  • Support
  • Contact
  • Login
ResearchServicesPricingPartnersAbout
ResearchServicesPricingPartnersAbout
  1. Home
  2. Research
  3. Horizons
  4. CRISPR-Cas9

CRISPR-Cas9

Bacterial-derived system for cutting and editing DNA at precise locations in living cells
Back to HorizonsView interactive version

CRISPR-Cas9 is a revolutionary gene-editing technology that uses a bacterial defense system adapted for precise DNA modification. The system consists of two components: a guide RNA that directs the system to a specific DNA sequence, and the Cas9 protein that cuts the DNA at that location. Once the DNA is cut, the cell's natural repair mechanisms can be harnessed to insert, delete, or modify genetic material. The technology makes genetic engineering dramatically easier, faster, and cheaper than previous methods, enabling precise edits in virtually any organism.

The technology has transformed genetic research and is enabling new medical treatments, agricultural improvements, and biotechnological applications. CRISPR can correct genetic mutations causing diseases, modify crops for improved traits, engineer cells for therapeutic purposes, and create research models of human diseases. The technology is being used in clinical trials for genetic diseases, cancer therapies, and other conditions. Applications include gene therapy for inherited diseases, cancer treatment using engineered immune cells, agricultural crops with improved traits, and research tools for understanding gene function. Companies like Editas Medicine, CRISPR Therapeutics, and various agricultural biotech firms are developing CRISPR applications.

At TRL 7, CRISPR-Cas9 is widely used in research and is being tested in clinical trials, with some therapies approved for specific conditions. The technology faces challenges including off-target effects where unintended DNA is edited, delivery to target cells in the body, immune responses to the editing system, and ethical concerns about germline editing and enhancement. However, as the technology improves and safety is demonstrated, applications expand. CRISPR could transform medicine by enabling cures for genetic diseases, revolutionize agriculture through precise crop improvement, and enable new biotechnological capabilities, though it also raises profound ethical questions about genetic modification, particularly for human germline editing and enhancement, requiring careful regulation and societal dialogue about appropriate uses.

TRL
7/9Operational
Impact
5/5
Investment
5/5
Category
Hardware

Related Organizations

Broad Institute of MIT and Harvard logo
Broad Institute of MIT and Harvard

United States · Research Lab

100%

A biomedical and genomic research center that holds key patents for the use of CRISPR-Cas9 in eukaryotic cells.

Researcher
Max Planck Unit for the Science of Pathogens

Germany · Research Lab

100%

A research institute founded to allow Emmanuelle Charpentier to continue her research into CRISPR-Cas9 and bacterial pathogens.

Researcher
CRISPR Therapeutics

Switzerland · Company

98%

A leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

Developer
Editas Medicine

United States · Company

95%

A clinical-stage genome editing company dedicated to developing a class of genomic medicines using CRISPR technology.

Developer
Intellia Therapeutics

United States · Company

95%

A biotechnology company developing curative therapeutics using CRISPR/Cas9 gene editing.

Developer
Beam Therapeutics

United States · Company

94%

A company pioneering the use of base editing, a new class of genetic medicines that offer precision gene editing.

Developer
Caribou Biosciences

United States · Company

93%

A clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies.

Developer
Mammoth Biosciences

United States · Startup

92%

A biotech company harnessing the diversity of nature to build the next generation of CRISPR products, specifically for diagnostics and ultra-compact editing.

Developer
Synthego

United States · Company

90%

A genome engineering company that provides synthetic RNA kits and engineered cells to accelerate CRISPR research.

Developer
eGenesis logo
eGenesis

United States · Company

89%

A company using CRISPR to engineer pig organs for human transplant (xenotransplantation).

Developer
Pairwise logo
Pairwise

United States · Company

88%

An agriculture technology company using CRISPR to develop new varieties of fruits and vegetables.

Developer
Tropic Biosciences

United Kingdom · Startup

85%

An agricultural biotechnology company using CRISPR to improve tropical crops like bananas, coffee, and rice.

Developer

Supporting Evidence

Evidence data is not available for this technology yet.

Connections

Hardware
Hardware
Genetic Reprogramming

Modifying gene expression to correct defects, silence genes, or transform cell types

TRL
4/9
Impact
5/5
Investment
5/5

Book a research session

Bring this signal into a focused decision sprint with analyst-led framing and synthesis.
Research Sessions